WO2005070966A3 - Fusion polypeptides capable of activating receptors - Google Patents

Fusion polypeptides capable of activating receptors Download PDF

Info

Publication number
WO2005070966A3
WO2005070966A3 PCT/US2005/001246 US2005001246W WO2005070966A3 WO 2005070966 A3 WO2005070966 A3 WO 2005070966A3 US 2005001246 W US2005001246 W US 2005001246W WO 2005070966 A3 WO2005070966 A3 WO 2005070966A3
Authority
WO
WIPO (PCT)
Prior art keywords
fusion polypeptides
polypeptides capable
fragment
antibody
activating receptors
Prior art date
Application number
PCT/US2005/001246
Other languages
French (fr)
Other versions
WO2005070966A2 (en
Inventor
James Fandl
Gang Chen
Nicholas Papadopoulos
Thomas H Aldrich
Original Assignee
Regeneron Pharma
James Fandl
Gang Chen
Nicholas Papadopoulos
Thomas H Aldrich
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma, James Fandl, Gang Chen, Nicholas Papadopoulos, Thomas H Aldrich filed Critical Regeneron Pharma
Priority to DE602005027309T priority Critical patent/DE602005027309D1/en
Priority to AU2005206536A priority patent/AU2005206536B2/en
Priority to JP2006549631A priority patent/JP4906094B2/en
Priority to DK05711471.2T priority patent/DK1709081T3/en
Priority to EP05711471A priority patent/EP1709081B1/en
Priority to AT05711471T priority patent/ATE504599T1/en
Priority to CA2550551A priority patent/CA2550551C/en
Publication of WO2005070966A2 publication Critical patent/WO2005070966A2/en
Publication of WO2005070966A3 publication Critical patent/WO2005070966A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Obesity (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

A fusion polypeptide comprising (A)x-M-(A’)Y, wherein A and A’ are each polypeptides capable of binding a target receptor. The fusion polypeptides of the invention form multimeric proteins which activate the target receptor. A and A’ may be each be an antibody or fragment derived form an antibody specific for a target receptor. The antibody or fragment may be the same or different ScFv fragments, and/or a ligand or ligand fragment, or derivative, capable of binding the target protein. M is a multimerizing component, and X and Y are independently a number between 1-10.
PCT/US2005/001246 2004-01-16 2005-01-14 Fusion polypeptides capable of activating receptors WO2005070966A2 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
DE602005027309T DE602005027309D1 (en) 2004-01-16 2005-01-14 FOR ACTIVATING RECEPTORS CAPABLE FUSION POLYPEPTIDES
AU2005206536A AU2005206536B2 (en) 2004-01-16 2005-01-14 Fusion polypeptides capable of activating receptors
JP2006549631A JP4906094B2 (en) 2004-01-16 2005-01-14 Fusion polypeptide capable of activating receptor
DK05711471.2T DK1709081T3 (en) 2004-01-16 2005-01-14 Fusion polypeptides that can activate receptors
EP05711471A EP1709081B1 (en) 2004-01-16 2005-01-14 Fusion polypeptides capable of activating receptors
AT05711471T ATE504599T1 (en) 2004-01-16 2005-01-14 FUSION POLYPEPTIDES CAPABLE OF ACTIVATING RECEPTORS
CA2550551A CA2550551C (en) 2004-01-16 2005-01-14 Fusion polypeptides capable of activating receptors

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US53696804P 2004-01-16 2004-01-16
US60/536,968 2004-01-16

Publications (2)

Publication Number Publication Date
WO2005070966A2 WO2005070966A2 (en) 2005-08-04
WO2005070966A3 true WO2005070966A3 (en) 2005-12-15

Family

ID=34807067

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/001246 WO2005070966A2 (en) 2004-01-16 2005-01-14 Fusion polypeptides capable of activating receptors

Country Status (10)

Country Link
US (1) US7534604B2 (en)
EP (1) EP1709081B1 (en)
JP (3) JP4906094B2 (en)
AT (1) ATE504599T1 (en)
AU (1) AU2005206536B2 (en)
CA (1) CA2550551C (en)
DE (1) DE602005027309D1 (en)
DK (1) DK1709081T3 (en)
ES (1) ES2364147T3 (en)
WO (1) WO2005070966A2 (en)

Families Citing this family (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
WO2003002609A2 (en) * 2001-06-28 2003-01-09 Domantis Limited Dual-specific ligand and its use
US20050271663A1 (en) * 2001-06-28 2005-12-08 Domantis Limited Compositions and methods for treating inflammatory disorders
US9321832B2 (en) * 2002-06-28 2016-04-26 Domantis Limited Ligand
CN1678634A (en) * 2002-06-28 2005-10-05 多曼蒂斯有限公司 Immunoglobulin single variable antigen combination area and its opposite constituent
US7696320B2 (en) 2004-08-24 2010-04-13 Domantis Limited Ligands that have binding specificity for VEGF and/or EGFR and methods of use therefor
EP1578801A2 (en) * 2002-12-27 2005-09-28 Domantis Limited Dual specific single domain antibodies specific for a ligand and for the receptor of the ligand
US8298532B2 (en) * 2004-01-16 2012-10-30 Regeneron Pharmaceuticals, Inc. Fusion polypeptides capable of activating receptors
EP1978032A3 (en) † 2004-07-22 2009-02-18 Erasmus University Medical Center Rotterdam Binding molecules
RS50785B (en) 2005-01-05 2010-08-31 F-Star Biotechnologische Forschungs-Und Entwicklungsges M.B.H. Synthetic immunoglobulin domains with binding properties engineered in regions of the molecule different from the complementarity determining regions
EP1912675B1 (en) 2005-07-25 2014-02-12 Emergent Product Development Seattle, LLC B-cell reduction using cd37-specific and cd20-specific binding molecules
BRPI0619225A2 (en) * 2005-12-01 2017-11-07 Domantis Ltd domain antibody monomer, ligand, isolated and recombinant nucleic acids, vector, host cell, method for producing a ligand dab monomer, pharmaceutical composition, drug delivery device, use of a domain antibody monomer, and, method to treat an inflammatory disease, arthritis or respiratory disease
US10183986B2 (en) 2005-12-15 2019-01-22 Industrial Technology Research Institute Trimeric collagen scaffold antibodies
US20070264687A1 (en) * 2005-12-15 2007-11-15 Min-Yuan Chou Recombinant triplex scaffold-based polypeptides
EP2002036A4 (en) * 2006-03-09 2010-01-27 Univ Texas Compositions and methods related to profiling a plurality of cell lines based on peptide binding
US8409577B2 (en) * 2006-06-12 2013-04-02 Emergent Product Development Seattle, Llc Single chain multivalent binding proteins with effector function
AT503889B1 (en) 2006-07-05 2011-12-15 Star Biotechnologische Forschungs Und Entwicklungsges M B H F MULTIVALENT IMMUNE LOBULINE
BRPI0812398A2 (en) * 2007-06-06 2019-09-24 Domantis Ltd anti-vegf immunoglobulin single variable domain, anti-vegf antagonist, protease resistant immunoglobulin simple variable domain, use of vegf antagonist, method for oral or drug delivery to a patient's gi tract or lung or lung tissue or a patient's eye, pulmonary dispensing device, oral formulation, double specific ligand, isolated or recombinant nucleic acid, vector, host cell, method for producing polypeptide, pharmaceutical composition, polypeptide, and fusion protein.
HUE066143T2 (en) 2007-06-26 2024-07-28 F Star Therapeutics Ltd Display of binding agents
EP2626371A1 (en) * 2007-07-31 2013-08-14 MedImmune, LLC Multispecific epitope binding proteins and uses thereof
EA021967B1 (en) 2008-01-03 2015-10-30 Дзе Скриппс Рисерч Инститьют Antibody targeting through a modular recognition domain
US8454960B2 (en) 2008-01-03 2013-06-04 The Scripps Research Institute Multispecific antibody targeting and multivalency through modular recognition domains
US8574577B2 (en) 2008-01-03 2013-11-05 The Scripps Research Institute VEGF antibodies comprising modular recognition domains
US8557243B2 (en) 2008-01-03 2013-10-15 The Scripps Research Institute EFGR antibodies comprising modular recognition domains
US8557242B2 (en) 2008-01-03 2013-10-15 The Scripps Research Institute ERBB2 antibodies comprising modular recognition domains
CN101970496B (en) 2008-03-14 2014-04-16 特朗斯吉有限公司 Antibody against the csf-1 r
US8470977B2 (en) 2008-03-14 2013-06-25 Transgene S.A. Antibody against the CSF-1R
JP6013733B2 (en) 2008-04-11 2016-10-25 エマージェント プロダクト デベロップメント シアトル， エルエルシー CD37 immunotherapeutic and its combination with bifunctional chemotherapeutics
EP2113255A1 (en) 2008-05-02 2009-11-04 f-star Biotechnologische Forschungs- und Entwicklungsges.m.b.H. Cytotoxic immunoglobulin
JP5823871B2 (en) * 2008-12-10 2015-11-25 アブリンクス エン．ヴェー． Amino acid sequences directed against the Angiopoietin / Tie system for the treatment of diseases and disorders associated with angiogenesis and polypeptides comprising the same
CN102711449B (en) 2009-12-10 2015-01-07 瑞泽恩制药公司 Mice that make heavy chain antibodies
KR101688522B1 (en) * 2009-12-15 2016-12-21 삼성전자주식회사 Angiopoietin-2 specific antibodies and uses thereof
JP5856073B2 (en) * 2009-12-29 2016-02-09 エマージェント プロダクト デベロップメント シアトル， エルエルシー RON binding construct and method of use thereof
US20130045492A1 (en) 2010-02-08 2013-02-21 Regeneron Pharmaceuticals, Inc. Methods For Making Fully Human Bispecific Antibodies Using A Common Light Chain
NZ719253A (en) 2010-02-08 2022-08-26 Regeneron Pharma Common light chain mouse
US9796788B2 (en) 2010-02-08 2017-10-24 Regeneron Pharmaceuticals, Inc. Mice expressing a limited immunoglobulin light chain repertoire
WO2011159847A2 (en) 2010-06-15 2011-12-22 The Regents Of The University Of California Receptor tyrosine kinase-like orphan receptor 1 (ror1) single chain fv antibody fragment conjugates and methods of use thereof
US20120100166A1 (en) 2010-07-15 2012-04-26 Zyngenia, Inc. Ang-2 Binding Complexes and Uses Thereof
EP2420253A1 (en) * 2010-08-20 2012-02-22 Leadartis, S.L. Engineering multifunctional and multivalent molecules with collagen XV trimerization domain
ES2634098T3 (en) 2011-01-14 2017-09-26 The Regents Of The University Of California Therapeutic antibodies against the ROR-1 protein and procedures for their use.
CA2837169C (en) 2011-05-24 2021-11-09 Zyngenia, Inc. Multispecific complexes comprising angiopoietin-2-binding peptide and their uses
SG2014007686A (en) 2011-08-05 2014-03-28 Regeneron Pharma Humanized universal light chain mice
SG11201405273YA (en) * 2012-02-29 2014-09-26 Gilead Biologics Inc Antibodies to matrix metalloproteinase 9
EP4310191A3 (en) 2012-06-14 2024-05-15 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule containing modified fc region
US9758591B2 (en) 2012-08-24 2017-09-12 The Regents Of The University Of California Antibodies and vaccines for use in treating ROR1 cancers and inhibiting metastasis
WO2014141192A1 (en) 2013-03-15 2014-09-18 Erasmus University Medical Center Generation of heavy chain-only antibodies
BR112015023752B1 (en) 2013-03-15 2023-11-14 Zyngenia, Inc. MODULAR RECOGNITION DOMAIN (MRD), COMPLEX COMPRISING MRD AND CETUXIMAB, USES OF THE COMPLEX TO INHIBIT ANGIOGENESIS AND TREAT CANCER AND PHARMACEUTICAL COMPOSITION COMPRISING SAID COMPLEX
CA2924252C (en) 2013-09-16 2022-01-04 Helmholtz Zentrum Munchen - Deutsches Forschungszentrum Fur Gesundheit Und Umwelt (Gmbh) Bi- or multispecific polypeptides binding immune effector cell surface antigens and hbv antigens for treating hbv infections and associated conditions
CN113307873A (en) * 2013-11-11 2021-08-27 中外制药株式会社 Antigen binding molecules comprising altered antibody variable regions
WO2015143414A2 (en) 2014-03-21 2015-09-24 Regeneron Pharmaceuticals, Inc. Non-human animals that make single domain binding proteins
RU2718692C2 (en) 2014-05-29 2020-04-13 Мэкроудженикс, Инк. Trispecific binding molecules, which specifically bind antigens of a variety of malignant tumors, and methods of using them
WO2015197582A1 (en) * 2014-06-27 2015-12-30 Innate Pharma Monomeric multispecific antigen binding proteins
US20160075772A1 (en) 2014-09-12 2016-03-17 Regeneron Pharmaceuticals, Inc. Treatment of Fibrodysplasia Ossificans Progressiva
WO2016044745A1 (en) 2014-09-19 2016-03-24 Regeneron Pharmaceuticals, Inc. Chimeric antigen receptors
US11154615B2 (en) 2014-11-11 2021-10-26 Chugai Seiyaku Kabushiki Kaisha Library of antigen-binding molecules including modified antibody variable region
SG11201706024YA (en) 2015-01-26 2017-08-30 Macrogenics Inc Multivalent molecules comprising dr5-binding domains
CN107438622A (en) 2015-03-19 2017-12-05 瑞泽恩制药公司 Non-human animal of the selection with reference to the light chain variable district of antigen
TWI773646B (en) 2015-06-08 2022-08-11 美商宏觀基因股份有限公司 Lag-3-binding molecules and methods of use thereof
MX2018001227A (en) 2015-07-30 2018-03-26 Macrogenics Inc Pd-1-binding molecules and methods use thereof.
KR20180053322A (en) 2015-09-21 2018-05-21 압테보 리서치 앤드 디벨롭먼트 엘엘씨 CD3 binding polypeptide
GEP20217317B (en) 2015-10-08 2021-11-10 Macrogenics Inc Combination therapy for the treatment of cancer
UA125611C2 (en) 2015-12-14 2022-05-04 Макродженікс, Інк. Bispecific molecules having immunoreactivity in relation to pd-1 and ctla-4, and methods of their use
UY37127A (en) 2016-02-17 2017-08-31 Macrogenics Inc MOLECULES OF UNION TO ROR1, AND METHODS OF USE OF THE SAME
EP3442574A4 (en) 2016-04-15 2019-12-11 MacroGenics, Inc. Novel b7-h3 binding molecules, antibody drug conjugates thereof and methods of use thereof
MY196869A (en) 2016-06-27 2023-05-05 Univ California Cancer treatment combinations
KR102630036B1 (en) 2016-12-23 2024-01-29 마크로제닉스, 인크. ADAM9-Binding Molecules, and Methods of Use Thereof
EP3585431A4 (en) 2017-02-24 2020-12-16 MacroGenics, Inc. Bispecific binding molecules that are capable of binding cd137 and tumor antigens, and uses thereof
US11952422B2 (en) 2017-12-05 2024-04-09 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule comprising altered antibody variable region binding CD3 and CD137
AU2018385409A1 (en) 2017-12-12 2020-07-02 Macrogenics Inc. Bispecific CD 16-binding molecules and their use in the treatment of disease
US11685781B2 (en) 2018-02-15 2023-06-27 Macrogenics, Inc. Variant CD3-binding domains and their use in combination therapies for the treatment of disease
US20210253685A1 (en) 2020-01-08 2021-08-19 Regeneron Pharmaceuticals, Inc. Treatment of fibrodysplasia ossificans progressiva
EP4126969A4 (en) 2020-03-31 2024-05-29 Chugai Seiyaku Kabushiki Kaisha Dll3-targeting multispecific antigen-binding molecules and uses thereof
US20240279353A1 (en) 2020-07-06 2024-08-22 Kiromic BioPharma, Inc. Mesothelin isoform binding molecules and chimeric pd1 receptor molecules, cells containing the same and uses thereof
WO2022108627A1 (en) 2020-11-18 2022-05-27 Kiromic Biopharma, Inc.Kiromic Biopharma, Inc. Gamma-delta t cell manufacturing processes and chimeric pd1 receptor molecules

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001090192A2 (en) * 2000-05-24 2001-11-29 Imclone Systems Incorporated Bispecific immunoglobulin-like antigen binding proteins and method of production
WO2003092611A2 (en) * 2002-05-03 2003-11-13 Regeneron Pharmaceuticals, Inc. Methods of inducing formation of functional and organized lymphatic vessels

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5955291A (en) * 1992-01-09 1999-09-21 Alitalo; Kari Antibodies recognizing tie receptor tyrosine kinase and uses thereof
US5747033A (en) 1993-10-28 1998-05-05 Regeneron Pharmaceuticals, Inc. Method of enhancing the biological activity of Eph family ligands
US5885574A (en) 1994-07-26 1999-03-23 Amgen Inc. Antibodies which activate an erythropoietin receptor

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001090192A2 (en) * 2000-05-24 2001-11-29 Imclone Systems Incorporated Bispecific immunoglobulin-like antigen binding proteins and method of production
WO2003092611A2 (en) * 2002-05-03 2003-11-13 Regeneron Pharmaceuticals, Inc. Methods of inducing formation of functional and organized lymphatic vessels

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DAVIS S ET AL: "LIGANDS FOR EPH-RELATED RECEPTOR TYROSINE KINASES THAT REQUIRE MEMBRANE ATTACHMENT OR CLUSTERING FOR ACTIVITY", 4 November 1994, SCIENCE, AMERICAN ASSOCIATION FOR THE ADVANCEMENT OF SCIENCE,, US, PAGE(S) 816-819, ISSN: 0036-8075, XP002038222 *
S. DAVIS ET AL: "Angiopoietins have distinct modular domains essential for receptor binding, dimerization and superclustering", NATURE STRUCTURAL BIOLOGY, vol. 10, no. 1, 2003, pages 38 - 44, XP008052277 *

Also Published As

Publication number Publication date
JP2007536912A (en) 2007-12-20
DE602005027309D1 (en) 2011-05-19
ATE504599T1 (en) 2011-04-15
JP2012040024A (en) 2012-03-01
JP4906094B2 (en) 2012-03-28
US7534604B2 (en) 2009-05-19
DK1709081T3 (en) 2011-06-06
CA2550551C (en) 2013-10-29
US20050158829A1 (en) 2005-07-21
AU2005206536B2 (en) 2010-09-02
JP2013031462A (en) 2013-02-14
JP5383780B2 (en) 2014-01-08
EP1709081B1 (en) 2011-04-06
AU2005206536A1 (en) 2005-08-04
WO2005070966A2 (en) 2005-08-04
EP1709081A2 (en) 2006-10-11
CA2550551A1 (en) 2005-08-04
ES2364147T3 (en) 2011-08-25

Similar Documents

Publication Publication Date Title
WO2005070966A3 (en) Fusion polypeptides capable of activating receptors
HK1211618A1 (en) Nogo receptor binding protein nogo
WO2005063816A3 (en) Monovalent antibody fragments useful as therapeutics
WO2007089601A3 (en) Nogo receptor antagonists
WO2004014311A3 (en) Nogo receptor antagonists
WO2004065416A3 (en) Synthetic antibody phage libraries
IS8339A (en) Anti-NOGO receptor antagonists
WO2003102157A3 (en) Synthetic antibody phage libraries
WO2006078431A3 (en) Compositions and methods related to modified retroviral vectors for restricted, site specific integration
WO2005028664A3 (en) Modulation of programmed necrosis
WO2007139846A3 (en) Bacterial expression of phosphorylated hsp20 and reagents therefor
WO2007144442A8 (en) P53 fusion proteins without transcription activity, and applications thereof
WO2001021794A3 (en) Smad associating polypeptides
WO2006020541A3 (en) Methods for synthesizing polypeptides

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2550551

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2005206536

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2006549631

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2005711471

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2005206536

Country of ref document: AU

Date of ref document: 20050114

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2005206536

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 2005711471

Country of ref document: EP